Autologous Cell-Derived Microparticles for Hemostasis

Solution Overview

Problem

Current treatments for bleeding disorders, such as platelet and clotting disorders, often involve allogeneic blood products that pose risks of blood-borne infections and immune reactions, and existing hemostatic agents have limitations in efficacy and safety, particularly in reducing excessive bleeding during trauma or surgical procedures.

Innovation Solution

The use of autologous or heterologous cell-derived microparticles, specifically red cell microparticles (RMP), which are generated from the patient's own blood and modified to express clotting factors like tissue factor and von Willebrand factor, to promote platelet adhesion and aggregation, thereby enhancing blood clot formation and reducing bleeding.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic blood products (platelets and coagulation factors) are used to treat bleeding disorders, then hemostatic efficacy is improved, but the risk of transmitting blood-borne infections and inducing immune reactions increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses the patient's own red blood cells to generate microparticles that express clotting factors, making the therapeutic agent autologous. This self-service approach eliminates the risk of immune reactions and blood-borne infections associated with allogeneic products, while maintaining hemostatic efficacy through the patient's own cellular machinery

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent introduces an intermediary system where red blood cells are engineered to express and present clotting factors on their surface or in association with microparticles. This intermediary approach allows clotting factors to be delivered in a controlled manner without direct transfusion of plasma or purified factors, reducing immunogenicity while maintaining function

Inventive Principle:
Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If recombinant clotting factors or small molecules are produced to avoid blood-borne infections, then safety is improved, but treatment cost increases and not all patients respond

Engineering Contradiction:
Core Design Contradiction:
Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent changes the physical and biological parameters of red blood cells by inducing expression of clotting factors through genetic modification or protein transduction. This parameter change allows the cells to function as living factories producing therapeutic factors, avoiding the high costs of recombinant production while ensuring patient-specific compatibility and response

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If human purified von Willebrand factor or cryoprecipitate is administered to treat clotting disorders, then clotting factor replacement is achieved, but clearance time is very short and some patients reject foreign proteins

Engineering Contradiction:
Core Design Contradiction:
Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent creates a composite system where clotting factors are associated with red blood cell membranes or microparticles. This composite structure provides a protective carrier that extends circulation time and reduces clearance, while the red blood cell matrix reduces immunogenicity by presenting the foreign proteins in a self-compatible context

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively reduces bleeding time, eliminates risks of immune reactions and blood-borne infections, and provides a safe, convenient, and cost-effective method for treating bleeding disorders by using the patient's own cells, thereby addressing the limitations of existing treatments.

Implementation Method 1

promote platelet adhesion, aggregation, blood clot formation

Methodology Applied
Scientific EffectPlatelet adhesion: Adhesive

Implementation Method 2

enhancing blood clot formation and reducing bleeding

Methodology Applied
Scientific EffectCoagulation: Coagulation

Data Source

PatentUS8105632B2Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
Publication Date: 2012.01.31
  • US8105632B2 patent drawing
  • US8105632B2 patent drawing
  • US8105632B2 patent drawing

AI summary

Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused by chemotherapy.